The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide
improve the behavioral phenotype and brain pathology in a transgenic mouse model
of Huntington disease”

Carole Escartin; Emmanuel Brouillet

doi:10.1016/j.freeradbiomed.2010.04.009

Journal Articles Free Radical Biology and Medicine Year : 2010

The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease”

(1) , (1)

1

Carole Escartin

Function : Author
PersonId : 175511
IdHAL : carole-escartin
ORCID : 0000-0003-3613-4118
IdRef : 104543213

Laboratoire des Maladies Neurodégénératives - UMR 9199

Emmanuel Brouillet

Function : Correspondent author
PersonId : 741138
IdHAL : emmanuelbrouilletceafr
ORCID : 0000-0001-6322-7403
IdRef : 07891924X

Connectez-vous pour contacter l'auteur

Laboratoire des Maladies Neurodégénératives - UMR 9199

Domains

Neurobiology

Carole Escartin : Connect in order to contact the contributor

https://hal-cea.archives-ouvertes.fr/cea-02168439

Submitted on : Friday, June 28, 2019-4:45:12 PM

Last modification on : Tuesday, May 9, 2023-11:18:06 AM

Dates and versions

cea-02168439 , version 1 (28-06-2019)

Identifiers

HAL Id : cea-02168439 , version 1
DOI : 10.1016/j.freeradbiomed.2010.04.009
PUBMED : 20399852

Cite

Carole Escartin, Emmanuel Brouillet. The Nrf2 pathway as a potential therapeutic target for Huntington disease. A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease”. Free Radical Biology and Medicine, 2010, 49 (2), pp.144-146. ⟨10.1016/j.freeradbiomed.2010.04.009⟩. ⟨cea-02168439⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

CEA CNRS JACOB CEA-DRF MIRCEN

14 View

0 Download